Furthermore, literature data showed that UCP-2 is involved also in cancer resistance, especially in paclitaxel resistance of lung cancer, in topoisomerase I inhibitor CPT-11 resistance of colon cancer and in gemcitabine resistance of pancreatic adenocarcinoma, non-small cell lung adenocarcinoma and bladder carcinoma [19]. This evidence concerns the gene UCP2 and urinary bladder carcinoma.